242 related articles for article (PubMed ID: 34569487)
1. The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse.
Gaulen Z; Brenna IH; Fadnes LT; Šaltytė Benth J; Solli KK; Kunoe N; Opheim A; Tanum L
Eur Addict Res; 2022; 28(1):56-67. PubMed ID: 34569487
[TBL] [Abstract][Full Text] [Related]
2. Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
Opheim A; Gaulen Z; Solli KK; Latif ZE; Fadnes LT; Benth JŠ; Kunøe N; Tanum L
Am J Addict; 2021 Sep; 30(5):453-460. PubMed ID: 34487395
[TBL] [Abstract][Full Text] [Related]
3. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Opheim A; Benth JŠ; Solli KK; Kloster PS; Fadnes LT; Kunøe N; Gaulen Z; Tanum L
Contemp Clin Trials; 2023 Dec; 135():107360. PubMed ID: 37865138
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
5. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
6. Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up.
Gaulen Z; Šaltytė Benth J; Fadnes LT; Brenna IH; Tanum L
J Subst Abuse Treat; 2022 Apr; 135():108656. PubMed ID: 34774396
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
8. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
9. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Greiner MG; Shulman M; Choo TH; Scodes J; Pavlicova M; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 Dec; 131():108447. PubMed ID: 34098301
[TBL] [Abstract][Full Text] [Related]
10. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
[TBL] [Abstract][Full Text] [Related]
11. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
13. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
14. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
[TBL] [Abstract][Full Text] [Related]
15. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
[TBL] [Abstract][Full Text] [Related]
16. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
[TBL] [Abstract][Full Text] [Related]
17. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
Marciuch A; Brenna IH; Weimand B; Solli KK; Tanum L; Røstad BK; Birkeland B
Addict Sci Clin Pract; 2022 Jul; 17(1):36. PubMed ID: 35850782
[TBL] [Abstract][Full Text] [Related]
18. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
[TBL] [Abstract][Full Text] [Related]
19. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
[TBL] [Abstract][Full Text] [Related]
20. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
